Deals
Teva to Buy Rimsa for About $2.3 Billion
- Teva to fund Mexican takeover with cash, lines of credit
- Rimsa to boost Teva earnings starting in first quarter 2017
This article is for subscribers only.
Teva Pharmaceutical Industries Ltd. agreed to buy Mexican drugmaker Representaciones e Investigaciones Médicas SA and some assets for $2.3 billion, furthering the Israeli company’s goal of expanding in emerging markets.
Rimsa, which had revenue of $227 million in 2014, will add to earnings from the first quarter of 2017, Petach Tikva, Israel-based Teva said in a statement on Thursday. The transaction will be completed in the early part of next year.